Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …

Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …

Background: COVID-19 has been linked to the development of many post–COVID-19
conditions (PCCs) after acute infection. Limited information is available on the effectiveness …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …

Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …

Background Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-
moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients …

Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …

Importance Postmarket analysis of individuals who receive nirmatrelvir and ritonavir
(Paxlovid [Pfizer]) is essential because they differ substantially from individuals included in …

Background Real-world data is currently limited on the association between oral antiviral
therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This …